Stevanato Group S.p.A. (NYSE:STVN) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. decreased its holdings in Stevanato Group S.p.A. (NYSE:STVNFree Report) by 8.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 416,174 shares of the company’s stock after selling 37,476 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Stevanato Group were worth $7,633,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Conestoga Capital Advisors LLC raised its holdings in Stevanato Group by 7.3% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 7,275,823 shares of the company’s stock worth $133,439,000 after purchasing an additional 496,930 shares during the period. Sands Capital Management LLC increased its stake in Stevanato Group by 1.6% during the 4th quarter. Sands Capital Management LLC now owns 1,884,330 shares of the company’s stock worth $51,423,000 after buying an additional 29,450 shares in the last quarter. Jackson Square Partners LLC increased its stake in Stevanato Group by 763.9% during the 1st quarter. Jackson Square Partners LLC now owns 1,824,240 shares of the company’s stock worth $58,558,000 after buying an additional 1,613,075 shares in the last quarter. Clearbridge Investments LLC increased its stake in Stevanato Group by 13.1% during the 1st quarter. Clearbridge Investments LLC now owns 1,729,397 shares of the company’s stock worth $55,514,000 after buying an additional 200,753 shares in the last quarter. Finally, William Blair Investment Management LLC increased its stake in Stevanato Group by 50.1% during the 1st quarter. William Blair Investment Management LLC now owns 1,432,868 shares of the company’s stock worth $45,995,000 after buying an additional 478,260 shares in the last quarter.

Stevanato Group Stock Up 2.4 %

STVN stock opened at €21.33 ($23.70) on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.13 and a current ratio of 1.74. The business has a 50 day simple moving average of €20.18 and a 200-day simple moving average of €22.42. Stevanato Group S.p.A. has a 1 year low of €16.56 ($18.40) and a 1 year high of €35.56 ($39.51).

Stevanato Group (NYSE:STVNGet Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported €0.09 ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.10 ($0.11) by (€0.01) (($0.01)). The company had revenue of €259.60 million during the quarter, compared to analysts’ expectations of €254.92 million. Stevanato Group had a net margin of 11.27% and a return on equity of 10.89%. Stevanato Group’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same quarter last year, the company earned $0.15 earnings per share. Sell-side analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Analyst Upgrades and Downgrades

STVN has been the subject of several research reports. Morgan Stanley cut their price objective on Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Citigroup cut their price objective on Stevanato Group from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Stevanato Group presently has an average rating of “Moderate Buy” and a consensus target price of €29.25 ($32.50).

View Our Latest Analysis on STVN

Stevanato Group Profile

(Free Report)

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.

See Also

Want to see what other hedge funds are holding STVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stevanato Group S.p.A. (NYSE:STVNFree Report).

Institutional Ownership by Quarter for Stevanato Group (NYSE:STVN)

Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.